Gelonghui, April 23 | Kingsley Biotechnology (01548.HK) issued an announcement. On April 22, 2024, Legend Biotech issued a press release announcing that the European Commission (EC) approved CARVYKTI(ciltacabtagene autoleucel, cilta-cel) is used to treat adult patients with recurrent and refractory multiple myeloma who have previously received at least one treatment, including proteasome inhibitors (PI) and immunomodulators (IMID). Patients showed disease progression during the last treatment, and lenalidomide was difficult to treat.
金斯瑞生物科技(01548.HK)：欧盟委员会批准CARVYKTI用于复发难治性多发性骨髓瘤患者二线治疗
Kingsley Biotechnology (01548.HK): The European Commission approved CARVYKTI for second-line treatment of patients with recurrent refractory multiple myeloma
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.